Literature DB >> 10571094

Routine SvO2 measurement after CABG surgery with a surgically introduced pulmonary artery catheter.

R Svedjeholm1, E Håkanson, Z Szabó.   

Abstract

OBJECTIVE: It has been argued that the poor correlation between cardiac output and mixed venous oxygen saturation (SvO2) reduces the value of SvO2. Routine use of Swan Ganz catheters is also controversial in cardiac surgery. Here our clinical experience with a simplified method for routine hemodynamic monitoring and the short-term prognostic value of SvO2 after CABG surgery is presented.
METHOD: Peroperatively an epidural catheter is routinely introduced through the outflow tract of the right ventricle into the pulmonary artery for monitoring of pressure and blood sampling. Clinical data were retrospectively retrieved from the records and related to SvO2 routinely obtained on admission to the ICU after 488 CABG procedures.
RESULTS: Average SvO2 on arrival to ICU was 67+/-7%. The SvO2 value of 55% represented a cut off point below which a high incidence of complications were found. Outcome after 456 procedures with SvO2 > or = 55% compared with 32 procedures with SvO2 < 55%: mortality 0 vs. 9.4% (P = 0.0003), perioperative myocardial infarction 6.2 vs. 29% (P < 0.0001), ventilator treatment 8.9+/-10.1 vs. 25.7+/-54.9 h (P = 0.0074), ICU stay 1.4+/-1.2 vs. 2.1+/-1.7 days (P = 0.0010).
CONCLUSIONS: SvO2 was of prognostic value and due to its specificity it seems particularly useful for telling which patients are unlikely to develop cardiorespiratory problems. Thus, this simple method for hemodynamic monitoring could contribute to cost containment as it seems that we can safely reserve Swan Ganz catheters for high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571094     DOI: 10.1016/s1010-7940(99)00287-0

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  End-tidal carbon dioxide monitoring indicates recovery from cardiogenic shock in patients receiving percutaneous cardiopulmonary support.

Authors:  Takuji Yoshida; Masazumi Watanabe; Mikiko Murakami; Hitoshi Furukawa; Hideki Nakahara
Journal:  J Artif Organs       Date:  2005       Impact factor: 1.731

2.  Central venous oxygen saturation during cardiopulmonary bypass predicts 3-year survival.

Authors:  Staffan Svenmarker; Sören Häggmark; Margareta Östman; Anders Holmgren; Ulf Näslund
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-12

3.  Mixed venous O2 saturation and fluid responsiveness after cardiac or major vascular surgery.

Authors:  Arjan N Kuiper; Ronald J Trof; A B Johan Groeneveld
Journal:  J Cardiothorac Surg       Date:  2013-09-22       Impact factor: 1.637

4.  Post hoc analysis of the glutamics-trial: intravenous glutamate infusion and use of inotropic drugs after cabg.

Authors:  Mårten Vidlund; Bashir Tajik; Erik Håkanson; Örjan Friberg; Jonas Holm; Farkas Vanky; Rolf Svedjeholm
Journal:  BMC Anesthesiol       Date:  2016-08-02       Impact factor: 2.217

5.  NT-proBNP and postoperative heart failure in surgery for aortic stenosis.

Authors:  Huiqi Jiang; Farkas Vánky; Henrik Hultkvist; Jonas Holm; Yanqi Yang; Rolf Svedjeholm
Journal:  Open Heart       Date:  2019-05-22

6.  Utility of NT-proBNP as an objective marker of postoperative heart failure after coronary artery bypass surgery: a prospective observational study.

Authors:  Huiqi Jiang; Jonas Holm; Örjan Friberg; Farkas Vanky; Mårten Vidlund; Bashir Tajik; Yanqi Yang; Rolf Svedjeholm
Journal:  Perioper Med (Lond)       Date:  2021-07-13

7.  The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study.

Authors:  Huiqi Jiang; Jonas Holm; Mårten Vidlund; Farkas Vanky; Örjan Friberg; Yanqi Yang; Rolf Svedjeholm
Journal:  J Transl Med       Date:  2020-05-11       Impact factor: 5.531

8.  Peripheral measurements of venous oxygen saturation and lactate as a less invasive alternative for hemodynamic monitoring.

Authors:  Raphaelle Avigael Chemtob; Hasse Møller-Sørensen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2018-09-10       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.